1. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs? Merck had a 14% increase in sales between 1997 and 1998 and 22% increase in sales from 1998 – 1999‚ and a 13% annual increase in earnings over the same period. Merck’s business strategy consists of two parts: (1) developing and marketing new drugs through internal research‚ and (2) developing partnerships with smaller biotechnology companies. Since 1995‚ Merck had launched
Premium Expected value License Money
Analysis on Merck: Conflict and change Assessment: Merck is one of the biggest pharmaceutical companies in the world today. Although encountered with success‚ it still faces many problems today while trying to be the market leader competing against its competition. While being research and development driven company‚ Merck now has to go beyond R&D to stay competitive in the pharmaceutical industry. The main issue that seems to come
Premium Pharmaceutical industry Pharmacology
including Bayer AG and Novartis are exploring a deal for Merck & Co Inc’s consumer healthcare business‚ as they seek to gain scale in a fragmented industry‚ according to several people familiar with the matter. Reckitt Benckiser Group PLC and Procter & Gamble Co are also among the parties that have held discussions with Merck about buying the unit‚ best known for Coppertone sunscreen and Claritin allergy medicine‚ the sources said this week. The Merck business‚ which also includes Dr. Scholl’s foot
Premium Pharmacology Marketing Pharmacy
Pharmaceuticals: Merck Sustaining Long-term Advantage Through Information Technology Hiroshi Amari Working Paper No. 161 Working Paper Series Center on Japanese Economy and Business Columbia Business School December 1998 Columbia-Yale Project: Use of Software to Achieve Competitive Advantage PHARMACEUTICALS: MERCK Sustaining Long-term Advantage Through Information Technology Prepared by Hiroshi Amari Research Associate‚ Yale University William V. Rapp and Hugh T. Patrick Co-principal
Premium Clinical trial Pharmaceutical industry Drug development
c. Moody’s Investors Service downgraded the long-term senior unsecured rating of AZN from A1 to Aa2 in 2007. Assess any potential association between this downgrade and AZN’s arrangements with Merck. Paris‚ July 30‚ 2007 -- Moody’s Investors Service downgraded the long-term senior unsecured ratings of AstraZeneca plc and its guaranteed subsidiary to A1 from Aa2. This downgrade followed the announcement of AstraZeneca’s acquisition of MedImmune for a total consideration of more than US$15 billion
Premium Money
J Bus Ethics DOI 10.1007/s10551-011-1130-4 Ethical Blindness Guido Palazzo • Franciska Krings • Ulrich Hoffrage Received: 1 June 2010 / Accepted: 22 November 2011 Ó Springer Science+Business Media B.V. 2011 Abstract Many models of (un)ethical decision making assume that people decide rationally and are in principle able to evaluate their decisions from a moral point of view. However‚ people might behave unethically without being aware of it. They are ethically blind. Adopting a sensemaking
Premium Decision making Morality Decision theory
Effects of Leadership in the Management Strategies of Merck and Company‚ Inc. Rana Satnani MGT-330 Management: Theory‚ Practice‚ and Application. July 2‚ 2010 Carolyn Harrison There lies a division in the business world between managers who “do things right” and leaders who “do the right things” (Bennis‚ 2007‚ p. 13). The primary difference between good managers and fantastic leaders is the ability to take risks and make independent decisions. Ethical leadership is more important today than
Premium Leadership Management Business ethics
Merck was at the top of the pharmaceutical market for many years. The company made substantial profits almost every year. Not only were they a company that made money but they also made their financial gains in an ethical manor. Fourton magazine even named them the “most admired” company. But in 2004‚ the company would be faced with major challenges that would threaten to end the company’s existence. Their once best selling painkiller Viol had been recalled by the federal government because the drug
Premium Pharmacology Pharmaceutical industry
Color blindness or color vision deficiency is the inability or decreased ability to see color‚ or distinguish color differences‚ under normal lighting conditions. Color blindness affects many people in a population. "Color blind" is a term of art; there is no actual blindness but there is a fault in the development of one or more sets of retinal cones that perceive color in light and transmit that inform ation to the optic nerve. Symptoms like those of color blindness can also be produced by physical
Premium Color
Questions for the Merck Case Create a decision tree for Merck. The 2 leftmost branches would identify the alternatives related to licensing Davarink (specifically license versus not to license). Next‚ if Merck decides to pursue license‚ they go into phase I which results in a success‚ or failure. Phase I success is followed by phase II where Merck has the opportunity to develop the drug to treat depression alone‚ weight loss alone‚ or both‚ or contemplate phase II failure. Finally phase
Premium Decision tree Decision theory